We are focused on developing differentiated products for the treatment and prevention of serious infectious diseases. Our clinical-stage programs include INX-189, a nucleotide polymerase inhibitor, and FV-100, a bicyclic nucleoside analogue, both of which are potent, orally available, antivirals in Phase 2 development for the treatment of chronic hepatitis C infections and herpes zoster (shingles), respectively, as well as Aurexis^®, a humanized monoclonal antibody in clinical development for the adjunct treatment of serious S. aureus infections in combination with antibiotics. Antiviral programs in pre-clinical development include several differentiated oral nucleotide analogues for the treatment of HCV. We have licensed the use of our MSCRAMM^® protein platform to Pfizer for use in the development of vaccines to prevent S. aureus infections.